Abeona Therapeutics (ABEO) vs Bicycle Therapeutics (BCYC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 12.7% versus a loss of 56.1%. Over five years, ABEO leads with a -78.3% price change compared with -93.4% for BCYC. Abeona Therapeutics is the larger company by market cap ($282.5 million vs $272.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | BCYC |
|---|---|---|
| Share price | $4.94 | $3.89 |
| Market cap | $282.49M | $272.27M |
| 1-day change | -0.40% | +2.10% |
| YTD return | -6.26% | -45.06% |
| 1-year return | -12.72% | -56.14% |
| 5-year return | -78.29% | -93.44% |
| EPS (TTM) | $-1.18 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $9.10 |
| 52-week low | $4.00 | $3.33 |
| Distance from 52-week high | -35.42% | -57.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +282.19% | +144.22% |
| Average volume | 1.39M | 387.29K |
| Shares outstanding | 57.18M | 50.55M |
| Employees | 226 | 288 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed BCYC by 43.4 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
ABEO vs BCYC FAQ
Which is bigger, Abeona Therapeutics or Bicycle Therapeutics?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $282.49M compared with $272.27M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, ABEO or BCYC?
ABEO returned -12.72% over the past 12 months, compared with -56.14% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Bicycle Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.